Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

These results are from EDITION I and EDITION II respectively and are part of the EDITION Phase 3 clinical program evaluating the efficacy and safety of the investigational new insulin U300 in people with diabetes.  The EDITION I data was presented at the 73rd Scientific Sessions of the American Diabetes Association.

"To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night," said Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study. "I am encouraged by these findings, and look forward to the results of the full Phase 3 EDITION program, which will further reveal how this investigational basal insulin may help people living with diabetes."

EDITION IAs the first study of the EDITION Phase 3 program, EDITION I evaluated the efficacy and safety of investigational new insulin U300, vs. Lantus® in people with type 2 diabetes using basal pl
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... N.Y. , Oct. 19, 2014  Henry Schein, ... provider of health care products and services to office-based ... it has invested in Iwase Dental Supply, Inc., a ... in Japan.  The transaction marks Henry Schein,s entrance into ... largest dental market, and increases to 28 the number ...
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3
... N.J., Feb. 27, 2012    Octapharma USA has submitted ... the U.S. Food and Drug Administration (FDA) with ... fourth quarter of 2012. The FDA will evaluate ... preoperative or bleeding patients who require replacement of multiple plasma ...
... ST. LOUIS, Feb. 27, 2012 Stereotaxis, Inc. (NASDAQ: ... release financial results for the fourth quarter and full ... 2012 after the close of the U.S. financial markets.  ... at 4:30 p.m. Eastern Time that day to discuss ...
Cached Medicine Technology:Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 2Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 3Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012 2Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012 3
(Date:10/20/2014)... Washington, D.C. (PRWEB) October 20, 2014 Zereana ... was crowned Mrs. Maryland 2014 on a platform to think ... battle scars, and uses her position to raise awareness about ... on awareness for breast cancer. You say the color pink ... “But I know for a fact that it has not ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... Medicare Claims Denials by 50% and IVANS LIME Is Ten Times ... ... 18, 2009 -- IVANS , the leading provider of corporate ... Verification solution has helped Mobile X-Ray Imaging Inc. significantly reduce ...
... DALLAS, Feb. 18 Every week more than 3,000 people in ... many find themselves with insufficient coverage or lack of insurance to ... , , The Limbs for Life Foundation ... and provide them with financial assistance to return to productive jobs ...
... their meat. Whether it,s rib eyes, pork chops or chicken ... country that more than 85 billion pounds of meat and ... a quarter of U.S. beef and pork is exported to ... the world,s largest consumer of meat, in Mexico, meat consumption ...
... pressure medication may be the key to preventing brain ... newly published study by researchers at Wake Forest University ... of an improved quality of life for cancer patients. ... a hypothesis from previous studies that a compound similar ...
... , A research group of the Universities of Granada ... food craving, an irresistible desire for eating certain foods (sweets, ... out by Professors Silvia Moreno Domnguez (University of ... and M Carmen Fernndez-Santaella ( University of Granada ...
... by Cop" (SBC) is a suicide method in which a ... an attempt to get oneself killed or injured by law ... Sciences examined the prevalence of this phenomenon among a ... SBC occurs at extremely high rates, with 36 percent of ...
Cached Medicine News:Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 2Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 3Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:Several studies prove self-banning certain foods may cause food craving 2Health News:'Suicide by cop' phenomenon occurring in over a third of North American shootings involving police 2
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
Medicine Products: